GlassScriptPhysician profile
Ashlyn Patterson
NPI 1285295873
$4,135.73
in general payments reported to CMS, 2019-2025
28 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $150 · 2021: $123 · 2022: $477 · 2023: $976 · 2024: $847 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,807 · Education: $77.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,807.37 |
| Education | $77.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,398.56 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $569.82 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $403.04 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $217.69 | 2019-2022 | |
| Pfizer INC. | $176.02 | 2019-2025 | |
| Lilly USA, LLC | $173.87 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $152.81 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $147.75 | 2022-2023 | |
| Allergan, INC. | $124.99 | 2019 | |
| Lundbeck LLC | $100.63 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $90.96 | 2023 | Auvelity |
| Exact Sciences Corporation | $73.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $59.25 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.89 | 2022-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $48.20 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $47.89 | 2022-2024 | Senza |
| Janssen Pharmaceuticals, INC | $46.65 | 2024-2025 | Spravato |
| Edwards Lifesciences Corporation | $34.76 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Sumitomo Pharma America, INC. | $34.66 | 2023 | Gemtesa |
| Abbott Laboratories | $28.21 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Itamar Medical INC | $26.19 | 2025 | Watchpatone |
| Sunovion Pharmaceuticals INC. | $24.90 | 2022 | |
| Organon LLC | $17.89 | 2025 | |
| Amgen INC. | $17.86 | 2024 | Repatha, Otezla |
| Masimo Corporation | $17.25 | 2022 | |
| Neos Therapeutics, LP | $16.67 | 2024 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $15.36 | 2022 | |
| Almatica Pharma LLC | $14.63 | 2023 | Loreev Xr, Sertraline Hcl, Gralise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlyn Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.